Creating a universal flu vaccine using plant-based technology.
Rapid Manufacturing of a Universal Flu Vaccine Using TMV-conjugated Centralized Antigens
This study is working on a new flu vaccine that could protect you from many different strains of the virus, using some cool new technology to make it stronger and longer-lasting, so you can stay healthier during flu season.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Lincoln NIH-funded |
| Lab location | 1 site (Lincoln, United States) |
| Project ID | NIH-10843257 on NIH RePORTER |
What this research studies
This research aims to develop a universal influenza vaccine that can provide broad immunity against various strains of the virus. By utilizing a combination of advanced technologies, including plant-based production methods and innovative vaccine conjugation techniques, the project seeks to enhance the potency and effectiveness of the vaccine. The approach involves producing specific viral proteins and analyzing immune responses in animal models to ensure long-lasting protection against seasonal flu variants. Patients may benefit from a more effective vaccine that could reduce the incidence of influenza and its complications.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at high risk for influenza complications, such as the elderly, young children, and those with underlying health conditions.
Not a fit: Patients who are not at risk for influenza or those who have already received a traditional flu vaccine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and broadly protective influenza vaccine for patients.
How similar studies have performed: Other research has shown promise in developing universal flu vaccines using similar innovative approaches, indicating potential for success.
Where this research is happening
Lincoln, United States
- University of Nebraska Lincoln — Lincoln, United States (Active)
Researchers
- Principal investigator: Weaver, Eric a — University of Nebraska Lincoln
- Study coordinator: Weaver, Eric a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.